Enliven Therapeutics, Inc. (ELVN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 41.25 |
| Open | 41.76 |
| Day High | 42.92 |
| Day Low | 41.59 |
| 52-Week High | 62.32 |
| 52-Week Low | 14.79 |
| Volume | 2.05M |
| Average Volume | 1.22M |
| Market Cap | 3.06B |
| PE | -25.04 |
| EPS | -1.67 |
| Moving Average 50 Days | 50.9 |
| Moving Average 200 Days | 42 |
| Change | 0.57 |
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
GlobeNewswire Inc.
Sep 28, 2024 1:35 PM GMT
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phas
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
GlobeNewswire Inc.
Sep 18, 2024 8:05 PM GMT
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inh